T cell-dependent suppression of antibody production. I. Characteristics of suppressor T cells following tolerance induction. 1978

A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie

Specific immunological tolerance was induced in adult CBA mice by a single injection of deaggregated human IgG (dHGG). Spleen cells taken 7 to 42 days later, produced consistent suppression of a DNP-HGG collaborative antibody response on adoptive transfer into heavily irradiated recipients. Noncentrifuged F(ab')2 fragments of HGG were as effective as dHGG in the production of suppressor cells. Suppression was antigen-specific since HGG-tolerant cells failed to abrogate either a DNP-keyhole limpet hemocyanin collaborative response or antibody production to the noncross-reactive antigen, horse erythrocytes. Pretreatment of the tolerant cell population with anti-Thy-1 serum and complement reversed the suppressive effect. However, purified tolerant T cells obtained by passage through nylon wool or anti-Ig columns were less effective than the original spleen cells in mediating suppression. Analysis of the cell types appearing in the column effluents indicated that the reduction in suppressive activity is best explained by retention of T cells rather than macrophages. Different T cell populations, however, were retained on the two types of columns. In the case of anti-Ig columns, these consisted of Ly-2,3+, Ia+ effector cells, whereas nylon wool columns caused depletion of Ly-1,2,3+ cells which are known to act as amplifiers of suppression. Suppression could not be explained in terms of delay in differentiation of antibody-forming cell precursors since the effect persisted for up to 15 days after transfer of tolerant cells. The demonstration of a reduction in serum anti-DNP and anti-HGG antibodies excluded the possibility of antibody production in sites other than the spleen. A role for anti-carrier antibody-antigen complexes in mediating the effector phase of suppression was rendered unlikely by the finding that the suppressive effect of tolerant cells persisted in the absence of detectable anti-HGG antibody production. Effector T cells mediating suppression in this system were shown to bear the phenotype Ia+, Ly-2,3+ as judged by the effect of pretreatment with appropriate antisera and complement. They were spleen-seeking, but were not detected in the thymus or recirculating lymphocyte pool. Adult thymectomy failed to cause a significant reduction in suppressive activity by tolerant spleen cells indicating that at least a major component of the immediate precursors is not of recent thymic origin.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D008297 Male Males
D008808 Mice, Inbred CBA An inbred strain of mouse that is widely used in BIOMEDICAL RESEARCH. Mice, CBA,Mouse, CBA,Mouse, Inbred CBA,CBA Mice,CBA Mice, Inbred,CBA Mouse,CBA Mouse, Inbred,Inbred CBA Mice,Inbred CBA Mouse
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody

Related Publications

A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
April 1976, The Journal of experimental medicine,
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
August 1972, Nature: New biology,
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
January 1984, International journal of immunopharmacology,
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
November 1976, Journal of immunology (Baltimore, Md. : 1950),
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
February 1984, The Australian journal of experimental biology and medical science,
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
September 1987, Transplantation,
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
February 1975, Journal of immunology (Baltimore, Md. : 1950),
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
May 1975, The Journal of experimental medicine,
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
July 2001, Journal of immunology (Baltimore, Md. : 1950),
A Basten, and J F Miller, and R Loblay, and P Johnson, and J Gamble, and E Chia, and H Pritchard-Briscoe, and R Callard, and I F McKenzie
February 1977, European journal of immunology,
Copied contents to your clipboard!